跳到正文
原文
STAT 主站· Adam Feuerstein·· 2026-10-15AI 评分18

华尔街生物科技板块遇冷:XBI指数自8月高点回落11%

STAT+: On Wall Street, there’s trouble stirring for biotech

AI 导读

生物科技投资者情绪因XBI指数自8月高点回落11%而转悲观。尽管该指数年内仍上涨24%,且跌幅低于2025年初的“生物科技严冬”水平,但表面数据下的深层问题正在引发资金流失和投资者焦虑。

正文

Many investors are losing money in what, on the surface, still seems like a positive year

Storm over beach
Adam Feuerstein/STAT

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox. And subscribe to STAT+ to get an unabridged version, with exclusive content.

Biotech investors were happy with the way the year was turning out. Then summer ended, and now, they are glum.

The XBI is still up 24%, although it’s down 11% from the August high. The retreat doesn’t look that alarming relative to the depths of the biotech winter experienced in early 2025. The real trouble, and the reason for investor angst, lies below the surface of the XBI’s performance.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

  1. Senior Writer, Biotech

    Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

来源:STAT 主站 · statnews.com